{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:46:32Z","timestamp":1756309592199,"version":"3.37.3"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Australian National Health and Medical Research Council for a Centre of Research Excellence","award":["APP2007007"],"award-info":[{"award-number":["APP2007007"]}]},{"name":"Investigator Grant","award":["APP2009736"],"award-info":[{"award-number":["APP2009736"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cerebral ventriculitis might be caused by Gram-negative bacteria, including ESBL producers. Temocillin may be a useful treatment option in this scenario; however, no consistent data are available regarding its penetration into the CSF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe the population pharmacokinetics of temocillin in plasma and CSF and to determine the probability for different simulated dosing regimens to achieve pharmacokinetic\/pharmacodynamic (PK\/PD) targets in the CSF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Ten post-neurosurgical critically ill adult patients requiring continuous drainage of CSF were included in this monocentric, prospective, open-label, non-randomized study. They received 2 g loading dose temocillin over 30 min IV infusion, followed by a 6 g continuous infusion over 24 h. Total and unbound concentrations were measured in plasma (n = 88 and 86) and CSF (n = 88 and 88) samples and used to build a population PK model. Monte Carlo simulations were performed to estimate the PTA at 100% Css&amp;gt;MIC (steady state concentration above the MIC) in CSF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All patients were infected with Enterobacterales with temocillin MICs \u22648 mg\/L. The median (min-max) temocillin penetration in CSF was 12.1% (4.3-25.5) at steady state. Temocillin unbound plasma pharmacokinetics were best described by a one-compartment model. PTA for the applied dosing regimen was &amp;gt;90% for bacteria with MIC \u2264 4 mg\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The currently approved dose of 6 g by continuous infusion may be adequate for the treatment of ventriculitis by Enterobacterales with MIC \u2264 4 mg\/L if considering 100% Css&amp;gt;MIC as the PK\/PD target to reach. Higher maintenance doses could help covering higher MICs, but their safety would need to be assessed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad398","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T13:15:16Z","timestamp":1703769316000},"page":"429-442","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetics and dosing simulations of total and unbound temocillin in the plasma and CSF of neurocritically ill patients with external ventricular drain-related cerebral ventriculitis"],"prefix":"10.1093","volume":"79","author":[{"given":"Perrin","family":"Ngougni Pokem","sequence":"first","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain , Avenue E. Mounier 73\/B1.73.05, B-1200, Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6124-7475","authenticated-orcid":false,"given":"Suzanne L","family":"Parker","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Verroken","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Department, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Collienne","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Cliniques universitaires St Luc, Universit\u00e9 catholique de Louvain , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Finet","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cliniques universitaires St Luc, Universit\u00e9 catholique de Louvain , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert-Jan","family":"Wijnant","sequence":"additional","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain , Avenue E. Mounier 73\/B1.73.05, B-1200 , Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Fran\u00e7ois","family":"Laterre","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A","family":"Roberts","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health , Brisbane , Australia"},{"name":"Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women\u2019s Hospital , Brisbane , Australia"},{"name":"Division of Anaesthesiology Critical Care Emergency and Pain Medicine, N\u00eemes University Hospital, University of Montpellier , N\u00eemes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-7991","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Van Bambeke","sequence":"additional","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain , Avenue E. Mounier 73\/B1.73.05, B-1200, Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Wittebole","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"2024020113261650400_dkad398-B1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11910-019-1010-3","article-title":"Management of elevated intracranial pressure: a review","volume":"19","author":"Changa","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2024020113261650400_dkad398-B2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00540-020-02795-7","article-title":"An overview of management of intracranial hypertension in the intensive care unit","volume":"34","author":"Schizodimos","year":"2020","journal-title":"J Anesth"},{"key":"2024020113261650400_dkad398-B3","doi-asserted-by":"crossref","first-page":"e00861-18","DOI":"10.1128\/JCM.00861-18","article-title":"Diagnostic approach to health care- and device-associated central nervous system infections","volume":"56","author":"Martin","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2024020113261650400_dkad398-B4","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1227\/neu.0000000000002301","article-title":"Internal ventricular cerebrospinal fluid shunt for adult hydrocephalus: a systematic review and meta-analysis of the infection rate","volume":"92","author":"Ramasy Razafindratovo","year":"2022","journal-title":"Neurosurgery"},{"key":"2024020113261650400_dkad398-B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12879-014-0712-z","article-title":"A meta-analysis of ventriculostomy-associated cerebrospinal fluid infections","volume":"15","author":"Ramanan","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2024020113261650400_dkad398-B6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/IDR.S326456","article-title":"Current perspectives on the diagnosis and management of healthcare-associated ventriculitis and meningitis","volume":"15","author":"Karvouniaris","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2024020113261650400_dkad398-B7","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw077","article-title":"Clinical characteristics and predictors of adverse outcome in adult and pediatric patients with healthcare-associated ventriculitis and meningitis","volume":"3","author":"Srihawan","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2024020113261650400_dkad398-B8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/cid\/cix005","article-title":"Management of ventriculoperitoneal shunt infections in adults: analysis of risk factors associated with treatment failure","volume":"64","author":"Pelegrin","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024020113261650400_dkad398-B9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/515003","article-title":"Antibiotic pharmacodynamics in cerebrospinal fluid","volume":"27","author":"Lutsar","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2024020113261650400_dkad398-B10","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/cid\/ciw861","article-title":"2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis","volume":"64","author":"Tunkel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024020113261650400_dkad398-B11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived","volume":"63","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dkl043","article-title":"Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England","volume":"57","author":"Livermore","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B13","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae","volume":"66","author":"Balakrishnan","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 5","key":"2024020113261650400_dkad398-B14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-198500295-00010","article-title":"Influence of temocillin on human bowel flora","volume":"29","author":"Mittermayer","year":"1985","journal-title":"Drugs"},{"key":"2024020113261650400_dkad398-B15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40262-017-0584-7","article-title":"Pharmacokinetics and pharmacodynamics of temocillin","volume":"57","author":"Alexandre","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 5","key":"2024020113261650400_dkad398-B16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2165\/00003495-198500295-00033","article-title":"A study of the penetration of temocillin in the cerebrospinal fluid","volume":"29","author":"Bruckner","year":"1985","journal-title":"Drugs"},{"author":"EUCAST.","key":"2024020113261650400_dkad398-B17"},{"key":"2024020113261650400_dkad398-B18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"2024020113261650400_dkad398-B19","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/jac\/dky314","article-title":"Therapeutic drug monitoring of beta-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures","volume":"73","author":"Wong","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B21","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkac286","article-title":"Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medications","volume":"77","author":"Ngougni Pokem","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B22","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/jac\/dkaa176","article-title":"Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial","volume":"75","author":"Matzneller","year":"2020","journal-title":"J Antimicrob Chemother"},{"author":"U.S. Department of Health and Human Services","key":"2024020113261650400_dkad398-B23"},{"key":"2024020113261650400_dkad398-B24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/ajcp\/16.3_ts.40","article-title":"An accurate and rapid method for the determination of proteins in small amounts of blood serum and plasma","volume":"10","author":"Weichselbaum","year":"1946","journal-title":"Am J Clin Pathol"},{"key":"2024020113261650400_dkad398-B25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0009-8981(71)90365-2","article-title":"Albumin standards and the measurement of serum albumin with bromcresol green","volume":"31","author":"Doumas","year":"1971","journal-title":"Clin Chim Acta"},{"key":"2024020113261650400_dkad398-B26","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/AAC.02355-14","article-title":"Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example","volume":"58","author":"Pai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113261650400_dkad398-B27","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF00315520","article-title":"Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man","volume":"45","author":"Nau","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"2024020113261650400_dkad398-B28"},{"key":"2024020113261650400_dkad398-B29","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2024020113261650400_dkad398-B30","first-page":"341","article-title":"Antimicrobial penetration into cerebrospinal fluid","volume":"15","author":"Richards","year":"1981","journal-title":"Drug Intell Clin Pharm"},{"key":"2024020113261650400_dkad398-B31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/AAC.30.3.481","article-title":"Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges","volume":"30","author":"Bakken","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113261650400_dkad398-B32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.diagmicrobio.2005.09.007","article-title":"Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies","volume":"54","author":"Lodise","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024020113261650400_dkad398-B33","doi-asserted-by":"crossref","first-page":"e01698-20","DOI":"10.1128\/AAC.01698-20","article-title":"Cerebrospinal fluid penetration of ceftolozane-tazobactam in critically ill patients with an indwelling external ventricular drain","volume":"65","author":"Sime","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113261650400_dkad398-B34","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/AAC.02570-12","article-title":"Microdialysis study of cefotaxime cerebral distribution in patients with acute brain injury","volume":"57","author":"Dahyot-Fizelier","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113261650400_dkad398-B35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijantimicag.2011.11.019","article-title":"Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury","volume":"39","author":"Poeppl","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2024020113261650400_dkad398-B36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13054-016-1523-y","article-title":"Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study","volume":"20","author":"Blassmann","year":"2016","journal-title":"Crit Care"},{"key":"2024020113261650400_dkad398-B37","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1128\/AAC.42.8.2012","article-title":"Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy","volume":"42","author":"Nau","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113261650400_dkad398-B38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-021-01061-7","article-title":"Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update","volume":"61","author":"Drwiega","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 3","key":"2024020113261650400_dkad398-B39","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1093\/clinids\/8.Supplement_3.S325","article-title":"Methods for evaluating the penetration of beta-lactam antibiotics into tissues","volume":"8","author":"Wise","year":"1986","journal-title":"Rev Infect Dis"},{"key":"2024020113261650400_dkad398-B40","doi-asserted-by":"crossref","first-page":"e0205221","DOI":"10.1128\/aac.02052-21","article-title":"Modelled target attainment after temocillin treatment in severe pneumonia: systemic and epithelial lining fluid pharmacokinetics of continuous versus intermittent infusions","volume":"66","author":"Layios","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113261650400_dkad398-B41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jac\/10.4.295","article-title":"Temocillin, in-vitro activity and the pharmacokinetics and tissue penetration in healthy volunteers","volume":"10","author":"Brown","year":"1982","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/12.1.93","article-title":"The intraperitoneal penetration of temocillin","volume":"12","author":"Wise","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B43","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/antibiotics11070898","article-title":"Population pharmacokinetics of temocillin administered by continuous infusion in patients with septic shock associated with intra-abdominal infection and ascitic fluid effusion","volume":"11","author":"Ngougni Pokem","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024020113261650400_dkad398-B44","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1128\/AAC.41.5.987","article-title":"Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients","volume":"41","author":"Nau","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113261650400_dkad398-B45","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1172\/JCI112407","article-title":"Morphologic alterations of the blood-brain barrier with experimental meningitis in the rat. Temporal sequence and role of encapsulation","volume":"77","author":"Quagliarello","year":"1986","journal-title":"J Clin Invest"},{"key":"2024020113261650400_dkad398-B46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkm467","article-title":"Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection","volume":"61","author":"De Jongh","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B47","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/jac\/dky078","article-title":"Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations","volume":"73","author":"Miranda Bastos","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B48","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jac\/dky489","article-title":"Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain","volume":"74","author":"Chauzy","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B49","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1111\/bcp.14657","article-title":"Population pharmacokinetics of vancomycin in patients with external ventricular drain-associated ventriculitis","volume":"87","author":"Jalusic","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2024020113261650400_dkad398-B50","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jac\/dkm325","article-title":"Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation","volume":"60","author":"Lodise","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.diagmicrobio.2007.03.015","article-title":"Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae","volume":"58","author":"Lodise","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024020113261650400_dkad398-B52","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1093\/jac\/dkac332","article-title":"Application of therapeutic drug monitoring to the treatment of bacterial central nervous system infection: a scoping review","volume":"77","author":"Arkell","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024020113261650400_dkad398-B53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00277654","article-title":"CSF shunt physics: factors influencing inshunt CSF flow","volume":"11","author":"Kadowaki","year":"1995","journal-title":"Childs Nerv Syst"},{"key":"2024020113261650400_dkad398-B54","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.medmal.2020.06.094","article-title":"Utilisation de la t\u00e9mocilline: \u00e9tude de cohorte","volume":"50","author":"Michelon","year":"2020","journal-title":"M\u00e9d Mal Infect"},{"key":"2024020113261650400_dkad398-B55","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/AAC.27.5.858","article-title":"Effect of temocillin and moxalactam on platelet responsiveness and bleeding time in normal volunteers","volume":"27","author":"Nunn","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"2024020113261650400_dkad398-B56","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/S1569-1993(10)60462-6","article-title":"Temocillin: time to rediscover it?","volume":"9","author":"Amaddeo","year":"2010","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/2\/429\/56418372\/dkad398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/2\/429\/56418372\/dkad398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:27:00Z","timestamp":1706794020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/2\/429\/7503109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,28]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad398","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,12,28]]}}}